Rituximab maintenance significantly prolongs progression‐free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation-Reference-Cited by-同舟云学术

Rituximab maintenance significantly prolongs progression‐free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation

Published:2018-12-13 Issue: Volume: Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Klener Pavel¹²^ORCID,Salek David³,Pytlik Robert¹,Mocikova Heidi⁴,Forsterova Kristina¹,Blahovcova Petra¹,Campr Vit⁵,Prochazka Vit⁶,Obr Ales⁶,Jaksa Radek⁷,Kuntscherova Jana⁸,Boudová Ludmila⁸,Kodet Roman⁵,Janikova Andrea³,Trneny Marek¹

Affiliation:

1. First Medical DepartmentCharles University General Hospital Prague Czech Republic

2. Institute of Pathological Physiology, First Faculty of MedicineCharles University Prague Czech Republic

3. Department of Hematology and OncologyMasaryk University Hospital Brno Czech Republic

4. Department of Internal Medicine and Haematology, Faculty Hospital Kralovske Vinohrady and Third Faculty of MedicineCharles University Prague Czech Republic

5. Department of Pathology and Molecular Medicine, Second Faculty of MedicineCharles University Hospital Motol Czech Republic

6. Department of Hemato‐Oncology, Faculty of Medicine and DentistryPalacky University and University Hospital Olomouc Olomouc Czech Republic

7. Institute of PathologyCharles University General Hospital Prague Czech Republic

8. Department of PathologyCharles University Medical Faculty Plzen Prague Czech Republic

Funder

Ministerstvo Zdravotnictví Ceské Republiky

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25362

Reference6 articles.

1. Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma

2. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur

3. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

4. Treatment of Older Patients with Mantle-Cell Lymphoma

5. High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023;Journal of the National Comprehensive Cancer Network;2023-11

2. Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial;Blood Advances;2023-07-18

3. Personalized approaches for treatment-naïve mantle cell lymphoma;Expert Review of Hematology;2023-02-01

4. Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic;Annals of Hematology;2022-11-11

5. Hematopoietic cell transplantation for mantle cell lymphoma;International Journal of Hematology;2022-01-29